Skip to content

Article: Nicotinamide Riboside and Pterostilbene Prevent UVB-Induced Skin Swelling and Immune Suppression: Preclinical Findings

Nicotinamide Riboside and Pterostilbene Prevent UVB-Induced Skin Swelling and Immune Suppression: Preclinical Findings


Synopsis

Exposure to ultraviolet B (UVB) radiation can cause skin inflammation, immune suppression, and long-term risks like skin cancer. This study tested whether nicotinamide riboside (NR), a vitamin B3–derived NAD+ precursor, and pterostilbene (PT), a plant-based antioxidant, could protect against UVB-induced damage in mice. After being fed diets containing NR, PT, or both, mice were exposed to UVB light. The combination of NR and PT reduced UVB-induced skin swelling (inflammation) more effectively than either compound alone. Both NR and PT also prevented UV-induced immune suppression, which normally weakens the skin’s ability to respond to harmful stimuli, with the combination offering the strongest protection. NR worked best at lower radiation doses, while PT was effective across both low and high UVB exposures. These findings suggest that NR and pterostilbene together enhance skin defense mechanisms, reducing inflammation and immune damage caused by UV radiation—potentially helping to prevent photoaging and skin cancer.

Journal

Photodermatology, Photoimmunology & Photomedicine

Read more

Cardiovascular Disease

Effects of Intravenous Nicotinamide Riboside on Doxorubicin-Related Organ Damage: Preclinical Findings

Synopsis Doxorubicin (DOX) is a powerful chemotherapy drug used to treat various cancers, but its use is limited by serious side effects that damage vital organs such as the heart, kidneys, liver,...

Read more
Cardiovascular Disease

Effects of Intravenous Nicotinamide Riboside on Doxorubicin-Related Organ Damage: Preclinical Findings

Synopsis Doxorubicin (DOX) is a powerful chemotherapy drug used to treat various cancers, but its use is limited by serious side effects that damage vital organs such as the heart, kidneys, liver,...

Read more